LENOVO
31.7.2024 15:01:34 CEST | Business Wire | Press release
Today, Lenovo has joined forces with Databricks to drive AI adoption amongst its customers. As a Databricks Consulting & Systems Integration (C&SI) Select Tier Partner, Lenovo will work with businesses to help them take advantage of enhanced data management capabilities, streamlining access to data from multiple sources and removing barriers to successful AI usage.
The offering will run through the Lenovo AI Center of Excellence (AI CoE), designed to help customers put AI to work for their organizations quickly, cost-effectively and at scale, with solutions that bring AI from ideation to reality. Working with the Databricks Data Intelligence Platform, Lenovo will help businesses to bring their data sources together, allowing them to increase the use of generative AI, improve their data analytics capabilities and drive innovation. The Lenovo AI Center of Excellence (AI CoE) will provide services to help customers define outcomes and rapidly innovate with the Databricks Platform to meet the unique needs of their organization.
“We’ve spoken to many customers at various stages of their AI journeys and, while most want to reap the benefits and feel the urgency to do so, their organizations aren’t ready,” commented Linda Yao, Chief Operating Officer and Head of Strategy, Lenovo Solutions & Services Group. “Our latest study showed that 90% of the CIOs we surveyed see AI as a game changer, yet over half feel their organizations lack the technical skills to scale AI quickly. By adding Databricks to Lenovo's ecosystem of leading software vendors, we can further enable our AI for all vision and bring the technology to a broader set of customers."
Starting in the Greater China and Asia Pacific Region, then rolling out globally, Lenovo will offer end-to-end expertise in solutions and services for data management, including cloud, data and AI strategy, data platform modernization, data migration, pre-built code for quick implementation, optimization, governance and audit management, and AI and ML use cases.
"Our partnership with Lenovo showcases our unwavering commitment to democratize data and AI for all organizations. We are proud to see our relationship with Lenovo transform from customer to key partner. Together, we are driving unprecedented innovation, accelerating growth, and delivering exceptional value to our customers on the Databricks Data Intelligence Platform," said Greg Taylor, VP of Partners, Databricks.
Lenovo was awarded partner status due to its broad and deep expertise in IT solutions, including over 10 years of public cloud solutions practice and rich operational experience gained in more than 15 years of data platform construction. The new offering forms part of Lenovo’s comprehensive AI Services practice that provides training and tools to help customers maximize their use of AI.
Based on insights from the recent Lenovo CIO report, most organizations struggle with how to deploy AI-powered solutions quickly, effectively, and securely. To support customers globally, Lenovo announced a comprehensive AI services portfolio aligned with the Gartner® Five Critical AI Adoption Phases. The Lenovo AI CoE aims to accelerate these services and use cases to deliver faster outcomes and improve efficiency by harnessing AI to unlock the value of their data.
"With an experienced and expert team on hand, our collaboration with Databricks will accelerate AI readiness and move customers closer to responsible and efficient AI adoption,” added Art Hu, SVP & CIO for Lenovo, and Chief Technology and Delivery Officer for Lenovo’s Solutions and Services Group. "From architecture and data management, through to implementation and governance, we can provide end-to-end solutions that remove obstacles to AI integration and help customers get to the benefits at pace."
A relationship built on Lenovo’s own experience with the Databricks Platform
Lenovo’s work with Databricks builds on a relationship that started in 2022, with Lenovo creating its own enterprise-level global data warehouse through Databricks and fundamental Azure services. Incorporating corporate common data models and 200 core KPIs to date, the warehouse supports the breadth of the organization, from product and production to supply, sales and services.
With its experience in digital and intelligent transformation and now as an implementation partner for Databricks, Lenovo is able to provide data and AI solutions based on Lenovo’s Hybrid Cloud infrastructure. The Lenovo and Databricks collaboration means customers will benefit from a modern data platform with streamlined data governance to help them accelerate their enterprise reporting and analytics and the adoption of AI applications.
About Lenovo
Lenovo is a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
LENOVO is a trademark of Lenovo. All other trademarks are the property of their respective owners. ©2024 Lenovo Group Limited.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731568838/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
